索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]孙雪烽,李建超,吴海波,等.PCSK9及其抑制剂在急性心肌梗死预防和治疗中的应用[J].国际心血管病杂志,2023,03:140-143.
点击复制

PCSK9及其抑制剂在急性心肌梗死预防和治疗中的应用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年03期
页码:
140-143
栏目:
综述
出版日期:
2023-05-30

文章信息/Info

Title:
-
作者:
孙雪烽; 李建超; 吴海波; 白世茹; 张丽娜; 杜荣品
050000 石家庄，河北医科大学研究生学院
Author(s):
-
关键词:
急性心肌梗死; 低密度脂蛋白胆固醇; 前蛋白转化酶枯草溶菌素9
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.03.004
文献标识码:
-
摘要:
低密度脂蛋白胆固醇（LDL-C）经氧化后沉积在冠状动脉内膜，是急性心肌梗死（AMI）的病变基础。前蛋白转化酶枯草溶菌素9（PCSK9）能够使血液循环中的LDL-C升高。PCSK9抑制剂可改善低密度脂蛋白受体的抑制状态，调控LDL-C水平。该文介绍PCSK9及其抑制剂在AMI防治中的研究进展。
Abstract:
-

参考文献/References

[1]Musunuru K. Treating coronary artery disease: beyond statins, ezetimibe, and PCSK9 inhibition[J]. Annu Rev Med, 2021, 72:447-458.
[2]Ferreira JP, Xhaard C, Lamiral Z, et al. PCSK9 protein and rs562556 polymorphism are associated with arterial plaques in healthy middle-aged population: the STANISLAS cohort[J]. J Am Heart Assoc, 2020, 9(7):e014758.
[3]Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2020, 41(24):2313-2330.
[4]Allahyari A, Jernberg T, Hagstr?m E, et al. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study[J]. Eur Heart J, 2020, 41(40):3900-3909.
[5]Da Dalt L, Castiglioni L, Baragetti A, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction[J]. Eur Heart J, 2021, 42(32):3078-3090.
[6]Tobert JA, Newman CB. Statin tolerability:in defence of placebo-controlled trials[J]. Eur J Prev Cardiol, 2016, 23(8):891-896.
[7]Bordicchia M, Spannella F, Ferretti G, et al. PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides[J]. Int J Mol Sci, 2019, 20(2):245.
[8]Mo?teoru S, Gai?? D, Banach M. An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity[J]. Expert Opin Drug Metab Toxicol, 2020, 16(12):1199-1205.
[9]Awan Z, Baass A, Genest J. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia[J]. Clin Chem, 2014, 60(11):1380-1389.
[10] Mikaeeli S, Susan-Resiga D, Girard E, et al. Functional analysis of natural PCSK9 mutants in modern and archaic humans[J]. FEBS J, 2020, 287(3): 515-528.
[11] Ferri N, Ruscica M, Coggi D, et al. Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study[J]. Atherosclerosis, 2020, 309:39-46.
[12] Evison BJ, Palmer JT, Lambert G, et al. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove[J]. Bioorg Med Chem, 2020, 28(6):115344.
[13] Ruscica M, Simonelli S, Botta M, et al. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(9):991-997.
[14] Macchi C, Banach M, Corsini A, et al. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels—experimental and clinical approaches with lipid-lowering agents[J]. Eur J Prev Cardiol, 2019, 26(9):930-949.
[15] Adorni MP, Zimetti F, Lupo MG, et al. Naturally occurring PCSK9 inhibitors[J]. Nutrients, 2020, 12(5):1440.
[16] Fitzgerald G, Kiernan T. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives[J]. Expert Rev Cardiovasc Ther, 2018, 16(8):567-578.
[17] Navarese EP, Ko?odziejczak M, Dimitroulis D, et al. From proprotein convertase subtilisin/kexin type 9 to its inhibition:state-of-the-art and clinical implications[J]. Eur Heart J Cardiovasc Pharmacother, 2016, 2(1):44-53.
[18] Wu CY, Tang ZH, Jiang L, et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway[J]. Mol Cell Biochem, 2012, 359(1):347-358.
[19] Kühnast S, van der Hoorn JWA, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[J]. J Lipid Res, 2014, 55(10):2103-2112.
[20] Reynolds VW, Chinn ME, Jolly JA, et al. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates[J]. J Clin Lipidol, 2019, 13(2): 254-264.
[21] Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3):results from the 4-year open-label extension of the ORION-1 trial[J]. Lancet Diabetes Endocrinol, 2023, 11(2):109-119.
[22] Almontashiri NAM, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies[J]. PLoS One, 2014, 9(9):e106294.
[23] Ferri N, Marchianò S, Tibolla G, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement[J]. Atherosclerosis, 2016, 253:214-224.
[24] Ding ZF, Wang XW, Liu SJ, et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy[J]. Cardiovasc Res, 2018, 114(13):1738-1751.
[25] Zhang Z, Wei TF, Zhao B, et al. Sex differences associated with circulating PCSK9 in patients presenting with acute myocardial infarction[J]. Sci Rep, 2019, 9(1):3113.
[26] Mi?ana G, Nú?ez J, Bayés-Genís A, et al. Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction:a pilot study[J]. ESC Heart Failure, 2020, 7(1):117-122.
[27] Wang J, Han P, Gao M, et al. Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI)[J]. Hellenic J Cardiol, 2022, 63:22-31.
[28] Murphy A, Hamilton G, Andrianopoulos N, et al. One-year outcomes of patients with established coronary artery disease presenting with acute coronary syndromes[J]. Am J Cardiol, 2019, 123(9):1387-1392.
[29] Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)[J]. J Am Coll Cardiol, 2019, 74(20):2452-2462.
[30] Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial[J]. J Am Coll Cardiol, 2019, 73(4):387-396.
[31] Bruckert E, Kereiakes DJ, Koren MJ, et al. PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: a pooled analysis of nine randomized-controlled studies of alirocumab[J]. J Clin Lipidol, 2019, 13(3):443-454.
[32] McKinley EC, Bittner VA, Brown TM, et al. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction[J]. J Clin Lipidol, 2022, 16(1):75-82.
[33] Lou BW, Liu H, Luo YB, et al. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction[J]. Lipids Health Dis, 2022, 21(1):105.
[34] Ma W, Pan Q, Pan D, et al. Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes:a systematic review and network Meta-Analysis[J]. Front Pharmacol, 2021, 12:713007.
[35] Schmidt AF, Carter JPL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease[J]. Cochrane Database Syst Rev, 2020, 10(10):CD011748.
[36] Tunoa JA, Billups SJ, Lowe RN, et al. Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation[J]. J Clin Lipidol, 2020, 14(6):784-790.
[37] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1):111-188.
[38] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2016, 37(39):2999-3058.
[39] Iannuzzo G, Gentile M, Bresciani A, et al. Inhibitors of protein convertase subtilisin/kexin 9 (PCSK9) and acute coronary syndrome (ACS): the state-of-the-art[J]. J Clin Med, 2021, 10(7):1510.

备注/Memo

备注/Memo:
基金项目：河北省科技厅重点研发计划项目（19277747D）
更新日期/Last Update: 2023-05-30